Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I ...

A 14-year-old male has been charged with attempted rape, reckless homicide and several other felonies in connection to an ...

NATICK, MASSACHUSETTS / ACCESS Newswire / January 22, 2025 / VALID, a Techbio startup dedicated to reshaping drug discovery with complex human ...

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and prim ...

MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The first IND submission is planned for the first half ...

Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...

Repair Biotechnologies, Inc. ( a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, is pleased to announce that it has ...

SYRACUSE, NEW YORK / ACCESS Newswire / January 21, 2025 / Repair Biotechnologies, Inc. ( a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, ...

Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications.

Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...